Pacific Biosciences of California, Inc. — Cyborg Score 6/10
Solid
DNA Sequencing
Strategic Profile
The company reported Q1 2026 revenue of $37.2 million (flat year-over-year) with consumable revenue of $21.8 million offsetting weaker instrument sales. GAAP gross margin improved to 35% from negative 4% a year ago, and GAAP net loss narrowed sharply to $8.3 million from $426.1 million. In February 2026, PacBio completed the sale of select short-read DNA sequencing assets to Illumina for $48.1 million in net cash proceeds, allowing the company to focus exclusively on long-read sequencing.
Cyborg Score Rationale
PacBio maintains an average "Buy" rating from 8 analysts with a 12-month stock price target of $2.46 (98% upside). The company demonstrated operational improvements and margin expansion in Q1 2026, but faces near-term headwinds from instrument sales pressures and elevated customer funding constraints.
Top Insights
(May 2026) Q1 2026 revenue flat at $37.2M, with record consumables revenue ($21.8M) offsetting weaker instrument sales; net loss narrowed to $8.3M from $426.1M year-over-year
(February 2026) Completed sale of short-read sequencing assets to Illumina for $48.1M, enabling strategic focus on long-read sequencing markets
(May 2026) EMEA revenue grew 17% year-over-year; clinical adoption expanding with new collaborations (Basecamp Research Trillion Gene Atlas, DNAstack federated genome dataset)
(May 2026) 2026 full-year revenue guidance set at $165M–$175M; new Revio SMRT Cells reduce sequencing costs by 30% while improving accuracy and epigenetic insights
Named Competitors
NovaSeq — Short-read sequencing platform
10x Genomics Solutions — Single-cell and spatial genomics tools